EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
In this multi-center open-label, non-randomized phase I/II intervention study three
consecutive doses of donor-derived EBV Tscm-CTLs will be administered to 10 patients with
treatment-refractory EBV lymphoma, diseases or PTLDs. EBV Tscm-CTLs will derive from
hematopoietic cell transplant (HCT) or third-party donors.